Ornithine
Transcarbamylase (OTC) Deficiency Treatment Market: Introduction
According to the report, the global ornithine transcarbamylase
(OTC) deficiency treatment market was valued at ~US$ 600 Mn in
2019. It is projected to expand at a CAGR of ~4% from 2020 to 2030.
Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder
characterized by partial or complete lack of the enzyme ornithine
transcarbamylase (OTC). OTC is one of six enzymes that play a role in the
breakdown and removal of nitrogen in the body, a process known as urea cycle.
Ammonia-scavenging drugs have been utilized in the treatment of urea cycle
disorders. Benzoate and Glycerol/Sodium Phenyl Butyrate (NaPB) target
liver-nitrogen metabolism by offering an alternative pathway for nitrogen
disposal through the urinary excretion of hippurate and phenylacetylglutamine.
A combination of a high biological value natural protein, an essential amino
acid formula and a calorie supplement without protein and essential amino acids
supplements may also be employed for the treatment of ornithine
transcarbamylase deficiency.
North America dominated the global ornithine
transcarbamylase (OTC) deficiency treatment market in 2019. It is expected to
dominate the global market, in terms of revenue, during the forecast period.
Rise in Prevalence of
Ornithine Transcarbamylase (OTC) Deficiency and Development of New Therapies to
Drive Global Market
The surge in the number of patients with ornithine
transcarbamylase (OTC) deficiency is likely fuel the global ornithine
transcarbamylase (OTC) deficiency treatment market. The development of new
therapies for ornithine transcarbamylase (OTC) deficiency treatment in the near
future and favorable reimbursement policies for OTC deficiency treatment
coupled with various patient assistance programs provided by several
international and regional organizations are major factors driving the global
ornithine transcarbamylase (OTC) deficiency treatment market.
For instance, in January 2020, The Assistance Fund (TAF),
an independent charitable patient assistance foundation that helps patients and
families facing high medical out-of-pocket costs, announced the launch of a new
financial assistance program for people living with urea cycle disorders.
Formulation modification for better patient compliance is also a key factor
driving the global ornithine transcarbamylase (OTC) deficiency treatment
market.
Ravicti to Dominate
Global Market
Based on product, the global ornithine transcarbamylase
(OTC) deficiency treatment market has been segmented into Buphenyl, Ravicti,
Ammonul, dietary supplements, and others. The Ravicti segment accounted for a
major share of the global market in 2019 due to higher efficacy and cost of
drug, and better patient compliance, which contributes toward higher revenues.
The Buphenyl segment followed the Raviciti segment, in terms of share of the
global market, in 2019, owing to pipeline products with improved patient
compliance and lesser cost to patients.
Request for Analysis of COVID19 Impact on
Ornithine Transcarbamylase Deficiency Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78569
Oral a Preferred Route of
Administration
In terms of route of administration, the global ornithine
transcarbamylase (OTC) deficiency treatment market has been bifurcated into
oral and intravenous. The oral segment dominated the global ornithine
transcarbamylase (OTC) deficiency treatment market in 2019. It is expected to
maintain its dominant share by 2030. Oral is also a highly lucrative segment.
It is projected to expand at a notable CAGR during the forecast period, owing
to patient preference for oral route and convenience offered by the oral route,
approval & launch of oral medication, availability of a large number of
products that can be administered through oral route, and new products with
improvement in formulation modification for taste masking.
Hospital Pharmacies to be
Key Distribution Channel
In terms of distribution channel, the global ornithine
transcarbamylase (OTC) deficiency treatment market has been divided into hospital
pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies
segment accounted for a major share of the market in 2019 due to higher number
of prescriptions filled at these hospital pharmacies, favorable reimbursement
scenario, strong supply chain management, and various patient assistance
programs run by pharmaceutical companies.
Competition Landscape
The global ornithine transcarbamylase (OTC) deficiency
treatment market is fragmented in terms of the number of players, with entry of
several new players. Key players in the global market include Abbott,
Nutricia (Danone Group), Mead Johnson (Reckitt Benckiser), Horizon Therapeutics
plc, Nestlé, Bausch Health Companies, Inc., Ultragenyx Pharmaceutical Inc.,
Arcturus Therapeutics, Inc., and Acer Therapeutics. Mergers, acquisitions
& strategic collaborations, distribution tie-ups, increased research &
development expenditure, and new product launches are major strategies adopted
by companies in the global ornithine transcarbamylase (OTC) deficiency
treatment market.
More Trending Reports by
Transparency Market Research:
About Us
Transparency Market Research is a global market
intelligence company, providing global business information reports and
services. Our exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants, use proprietary
data sources and various tools and techniques to gather, and analyze
information.
Our data repository is continuously updated and revised
by a team of research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability, Transparency Market
Research employs rigorous primary and secondary research techniques in developing
distinctive data sets and research material for business reports.
Contact
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
